PARP1 and hepatocellular carcinoma: Additionally, the PARP inhibitor Olaparib broadly suppresses DNA damage repair signaling and may enhance the overall remodeling of the pluripotency transcriptome, thereby improving the efficacy of Sorafenib in eliminating residual HCC tumors.